Evidence map›Paper›PMID 41198996›Full record

ArticleOphthalmology and therapy2026

Photobiomodulation Therapy with Low-Level Light in Chronic Central Serous Chorioretinopathy: A Pilot Study.

Claudio Iovino, Alba Chiara Termite, Giacomo Boscia, Carmela Sannace, Francesco Boscia, Giuseppe Giannaccare, Pasquale Viggiano

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Claudio IovinoMultidisciplinary Department of Medical, Surgical and Dental Sciences, Eye Clinic, University of Campania Luigi Vanvitelli, Naples, Italy.
Alba Chiara TermiteDepartment of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro", Piazza Giulio Cesare,11, Bari, Italy.
Giacomo BosciaDepartment of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro", Piazza Giulio Cesare,11, Bari, Italy.
Carmela SannaceASL Bari, Bari, Apulia, Italy.
Francesco BosciaDepartment of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro", Piazza Giulio Cesare,11, Bari, Italy.
Giuseppe GiannaccareDepartment of Surgical Sciences, Eye Clinic, University of Cagliari, Cagliari, Italy.
Pasquale ViggianoDepartment of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro", Piazza Giulio Cesare,11, Bari, Italy. pasquale.viggiano@uniba.it.ORCID http://orcid.org/0000-0002-0323-967X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe purpose of this study is to evaluate the anatomical and functional outcomes of photobiomodulation (PBM) in patients with chronic central serous chorioretinopathy (cCSC).

methodsIn this retrospective study, ten eyes from nine patients with cCSC were treated with PBM. All patients had persistent subretinal fluid (SRF) for ≥ 6 months and no history of prior laser therapy. PBM was delivered once a week for 4 weeks, then monthly for two additional months using a dual-wavelength (590 and 625 nm) protocol delivered through the eye-light® device. Anatomical and functional outcomes were assessed at baseline and 6 months through multimodal imaging and best-corrected visual acuity (BCVA).

resultsMean patient age was 45.37 years. At 6 months, mean BCVA improved significantly from 67.12 (±4.96) to 77.87 (±7.77) ETDRS letters (p = 0.0053). SRF completely resolved in 70% of eyes, partially improved in 10%, and remained unchanged in 20%. Among five eyes with serous avascular pigment epithelial detachment (PED), two PEDs resolved, one partially regressed, and two were unchanged. No adverse events were reported.

conclusionsPBM may be beneficial in improving retinal anatomy and visual function in cCSC, with an excellent safety profile. These findings support PBM as a promising noninvasive treatment modality in patients with cCSC. Prospective controlled trials are warranted to validate its efficacy and durability.

Indexed as

Central serous chorioretinopathyChronic CSCLow-level light therapyPhotobiomodulationPigment epithelial detachmentRetinaSubretinal fluidVisual acuity

Identifiers

PMID41198996
PMCPMC12882886

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.